Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IRON
Upturn stock ratingUpturn stock rating

Disc Medicine Inc. (IRON)

Upturn stock ratingUpturn stock rating
$54.5
Last Close (24-hour delay)
Profit since last BUY2.69%
upturn advisory
Strong Buy
BUY since 13 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: IRON (3-star) is a STRONG-BUY. BUY since 13 days. Profits (2.69%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

11 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $98.27

Year Target Price $98.27

Analyst’s Price TargetsFor last 52 week
$98.27Target price
Low$30.82
Current$54.5
high$68.73

Analysis of Past Performance

Type Stock
Historic Profit 102.56%
Avg. Invested days 39
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.89B USD
Price to earnings Ratio -
1Y Target Price 98.27
Price to earnings Ratio -
1Y Target Price 98.27
Volume (30-day avg) -
Beta 2.5
52 Weeks Range 30.82 - 68.73
Updated Date 06/28/2025
52 Weeks Range 30.82 - 68.73
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.89

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -16.25%
Return on Equity (TTM) -23.34%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1224761277
Price to Sales(TTM) -
Enterprise Value 1224761277
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -7.56
Shares Outstanding 34634300
Shares Floating 26710661
Shares Outstanding 34634300
Shares Floating 26710661
Percent Insiders 10.57
Percent Institutions 98.94

Analyst Ratings

Rating 4.73
Target Price 98.27
Buy 3
Strong Buy 8
Buy 3
Strong Buy 8
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Disc Medicine Inc.

stock logo

Company Overview

overview logo History and Background

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Founded in 2017, the company has focused on targeting fundamental pathways of iron metabolism to address diseases of erythropoiesis, heme synthesis, and iron overload.

business area logo Core Business Areas

  • Hematology: Development of therapies for hematologic diseases, including those related to red blood cell disorders and iron metabolism.
  • Erythropoiesis: Focus on improving the production of red blood cells in patients with conditions like anemia.
  • Heme Synthesis: Developing therapies focused on targeting heme synthesis pathways.

leadership logo Leadership and Structure

The leadership team includes experienced executives and scientists in drug development and hematology. The company has a board of directors with expertise in biotechnology and finance. Specific names and organizational charts can be found on their investor relations website.

Top Products and Market Share

overview logo Key Offerings

  • Bitopertin: A GlyT1 inhibitor for erythropoietic porphyrias (EPP) and X-linked protoporphyria (XLP). The target market is patients with EPP and XLP, which are rare genetic disorders. Competitors would be companies developing other treatments for these rare disorders, with limited comparable data currently.
  • DISC-0974: An anti-hemojuvelin (HJV) antibody being developed for anemia of inflammation, including myelofibrosis. There are also plans to look at additional clinical indications such as in Diamond-Blackfan anemia and chronic kidney disease.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with a growing focus on precision medicine and targeted therapies. Hematology, in particular, sees significant research and development activity due to the unmet needs of patients with blood disorders.

Positioning

Disc Medicine is positioned as a company developing novel therapies for hematologic diseases, particularly those related to iron metabolism and red blood cell production. The company's competitive advantage lies in its targeted approach to addressing the root causes of these diseases.

Total Addressable Market (TAM)

The TAM for hematologic disease therapies is substantial and expanding with the rise in rare diseases. Given Disc Medicine's focus on rare anemias the TAM would be approximately $2 - $5 billion dollars based on related markets. The company is well positioned to capture a portion of this market with successful clinical trials and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates targeting specific pathways in hematology
  • Experienced leadership team
  • Strong intellectual property portfolio
  • Focus on rare diseases with unmet medical needs

Weaknesses

  • Reliance on clinical trial success
  • Limited commercialization experience
  • Dependence on funding for research and development
  • Product pipeline in early stages

Opportunities

  • Expansion of pipeline into additional hematologic diseases
  • Partnerships with larger pharmaceutical companies
  • Accelerated regulatory pathways for orphan drugs
  • Advancements in personalized medicine

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Changes in regulatory environment
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • CRSP
  • BLUE
  • GBT

Competitive Landscape

Disc Medicine competes with established pharmaceutical companies and biotechnology firms developing therapies for hematologic diseases. Its competitive advantage lies in its focus on novel targets and its pipeline of differentiated drug candidates. It must compete against companies with more resources.

Growth Trajectory and Initiatives

Historical Growth: Disc Medicine's growth is primarily driven by its clinical development programs. Historical growth is tied to funding rounds and milestone achievements in its clinical trials.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals of its drug candidates. Analyst estimates vary, but generally reflect positive outlooks if clinical milestones are met.

Recent Initiatives: Recent initiatives include advancing its clinical trials for Bitopertin and DISC-0974 and exploring new indications for its drug candidates.

Summary

Disc Medicine is a clinical-stage biopharmaceutical company with a focus on hematologic diseases. The company's strength lies in its novel drug candidates and experienced leadership team. Its weaknesses include its reliance on clinical trial success and limited commercialization experience. While the company has several opportunities, it faces threats from competitors and regulatory changes.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Disc Medicine Inc. website
  • SEC filings
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Disc Medicine Inc.

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2020-08-12
CEO, President & Director Dr. John D. Quisel Esq., J.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 94
Full time employees 94

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.